利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

303 条记录 (耗时 0.032 秒)

    USE OF HLA-B*1301 ALLELE
    14.
    发明公开
    USE OF HLA-B*1301 ALLELE 有权
    VERWENDUNG VON HLA-B * 1301-ALLEL

    公开(公告)号：EP2787085A1

    公开(公告)日：2014-10-08

    申请号：EP13849836.5

    申请日：2013-06-18

    申请人： Shandong Provincial Institute of Dermatology and Venereology

    发明人： ZHANG, Furen ,  CHEN, Shumin ,  LIU, Hong

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6881 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： The present invention discloses uses of a HLA-B*1301 allele, comprising: 1) a use of a substance for detecting whether a person has the HLA-B*1301 allele in preparation of a product for evaluating a risk of adverse drug reactions in response to dapsone in the person; 2) a method for detecting or evaluating a risk of adverse drug reaction in response to dapsone in a person, comprising detecting whether the person has the HLA-B*1301 allele, wherein, a person with LA-B*1301 allele suffers a higher risk of adverse drug reaction upon being administered dapsone, as compared with a person without HLA-B*1301 allele, and a person with LA-B*1301 alleles at both chromosomes of a pair of homologous chromosomes suffers a higher risk of adverse drug reaction upon being administered dapsone, as compared with a person with HLA-B*1301 allele at only one of a pair of homologous chromosomes.

    摘要翻译： 本发明公开了HLA-B * 1301等位基因的用途，其包括：1）在制备用于评估药物不良反应风险的产品时，用于检测人是否具有HLA-B * 1301等位基因的物质的用途 对人体内的氨苯砜的反应; 2）一种用于检测或评估对人的氨苯砜作出反应的不良药物反应的风险的方法，包括检测该人是否具有HLA-B * 1301等位基因，其中，具有LA-B * 1301等位基因的人遭受更高 与没有HLA-B * 1301等位基因的人相比，施用氨苯砜后药物不良反应的风险，以及一对同源染色体两条染色体上具有LA-B * 1301等位基因的人遭受不良药物反应的较高风险 与一对同源染色体中只有一个具有HLA-B * 1301等位基因的人相比，施用氨苯砜后。

    GLUCOSE SENSOR CALIBRATION
    15.
    发明公开
    GLUCOSE SENSOR CALIBRATION 审中-公开
    葡萄糖传感器校准

    公开(公告)号：EP2780715A1

    公开(公告)日：2014-09-24

    申请号：EP12798346.8

    申请日：2012-11-16

    申请人： Lightship Medical Limited

    发明人： CRANE, Barry Colin ,  PATERSON, William

    IPC分类号： G01N33/66 ,  A61B5/145 ,  A61B5/1495 ,  G01N27/327

    CPC分类号： G01N27/3274 ,  A61B5/14532 ,  A61B5/1459 ,  A61B5/1495 ,  G01N33/66

    摘要： A method of calibrating a glucose sensor, which method comprises: (a) preparing a first glucose-containing calibration solution by combining water or an aqueous solution with alpha and beta glucose, the alpha and beta glucose being provided in solid form; (b) exposing a glucose sensor to said first glucose-containing calibration solution and determining the sensor output; (c) exposing the glucose sensor to one or more further calibration solutions having different glucose concentrations from each other and from said first glucose-containing calibration solution and determining the sensor output for the or each calibration solution; and (d) determining a calibration curve from the sensor output data collected in steps (b) and (c); wherein the first glucose-containing calibration solution of step (a),and if used the or each glucose-containing calibration solution of step (c), is prepared using 25 to 50 % alpha glucose and 50 to 75 % beta glucose, and wherein the first glucose-containing calibration solution of step (a), and if used the or each glucose-containing calibration solution of step (c), is prepared by combining water or an aqueous solution with freeze-dried glucose.

    TUMOR CHEMOTHERAPEUTIC DRUG FORMULATION AND PREPARATION METHOD THEREOF
    17.
    发明公开
    TUMOR CHEMOTHERAPEUTIC DRUG FORMULATION AND PREPARATION METHOD THEREOF 有权
    肿瘤化疗药物制剂及其制备方法

    公开(公告)号：EP2749292A1

    公开(公告)日：2014-07-02

    申请号：EP12825203.8

    申请日：2012-01-19

    申请人： Hubei Soundny Biotechnology Co., Ltd. ,  Huang, Bo

    发明人： HUANG, Bo

    IPC分类号： A61K47/46 ,  A61K45/00 ,  A61P35/00

    CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K9/5068 ,  A61K9/5089 ,  A61K31/519 ,  A61K31/704 ,  A61K33/24 ,  A61K35/13 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides a pharmaceutical preparation for tumor chemotherapy and a method for producing the same, the pharmaceutical preparation for tumor chemotherapy comprises cell vesicles derived from apoptotic tumor cells and chemotherapeutic drugs as active ingredients wrapped within the cell vesicles. The chemotherapeutic drugs contained within the pharmaceutical preparation are chemotherapeutic drugs containing active ingredients for the treatment of the tumors from which the cell vesicles are provided. The present invention also provides a method for producing the pharmaceutical preparation for tumor chemotherapy. The technical solutions provided by the present invention can selectively release the chemotherapeutic drugs to the tumor sites and maintain lasting medicinal effect, increasing their killing effects against tumor cells and reducing the toxic side-effect of the chemotherapeutic drugs to normal cells.

    摘要翻译： 本发明提供用于肿瘤化疗的药物制剂及其制备方法，用于肿瘤化疗的药物制剂包含源自凋亡肿瘤细胞的细胞囊泡和化疗药物作为包裹在细胞囊泡内的活性成分。 包含在药物制剂中的化学治疗药物是含有活性成分的化疗药物，用于治疗提供细胞囊泡的肿瘤。 本发明还提供了一种生产肿瘤化疗药物制剂的方法。 本发明提供的技术方案能够选择性地将化疗药物释放到肿瘤部位，保持药效持久，增强对肿瘤细胞的杀伤作用，降低化疗药物对正常细胞的毒副作用。

    OPTICAL GLUCOSE BIOSENSOR CALIBRATION USING DIFFERENT TEMPERATURE CALIBRATION SOLUTIONS
    18.
    发明公开
    OPTICAL GLUCOSE BIOSENSOR CALIBRATION USING DIFFERENT TEMPERATURE CALIBRATION SOLUTIONS 审中-公开
    光学葡萄糖生物传感器校准使用不同的温度校准解决方案

    公开(公告)号：EP2715369A1

    公开(公告)日：2014-04-09

    申请号：EP12729693.7

    申请日：2012-05-25

    申请人： LIGHTSHIP MEDICAL LIMITED

    发明人： BARWELL, Nicholas Paul ,  EDGLEY, Peter ,  MACKENZIE, Alasdair Allan ,  PATERSON, William ,  CRANE, Barry Colin

    IPC分类号： G01N33/58 ,  G01N33/66

    CPC分类号： G01K15/005 ,  G01N33/5438 ,  G01N33/582 ,  G01N33/66

    摘要： A method of calibrating a reversible-binding sensor for detecting an analyte includes: (i) varying the temperature of a first calibration solution from a first temperature (T1) to a second temperature (T2) while the first calibration solution is in contact with a sensing region of the sensor; (ii) determining the sensor output for the first calibration solution as a function of temperature; (iii) varying the temperature of a second calibration solution from a third temperature (T3) to a fourth temperature (T4) while the second calibration solution is in contact with the sensing region, the second calibration solution having a concentration of analyte which is different from that of the first calibration solution; (iv) determining the sensor output for the second calibration solution as a function of temperature; and (v) using the determined sensor output from steps (ii) and (iv) to calibrate the sensor.

    摘要翻译： 校准用于检测分析物的可逆结合传感器的方法包括：（i）当第一校准溶液与第一校准溶液接触时，将第一校准溶液的温度从第一温度（T1）改变到第二温度（T2） 传感器的感测区域; （ii）确定作为温度函数的第一校准溶液的传感器输出; （iii）当所述第二校准溶液与所述感测区域接触时，将第二校准溶液的温度从第三温度（T3）改变为第四温度（T4），所述第二校准溶液具有不同的分析物浓度 从第一个校准解决方案的; （iv）根据温度确定第二校准溶液的传感器输出; 和（v）使用步骤（ii）和（iv）中确定的传感器输出来校准传感器。

    Raw pipe of Fe-Ni Alloy and method for production thereof
    19.
    发明公开
    Raw pipe of Fe-Ni Alloy and method for production thereof 审中-公开
    Fe-Ni-Legierungsrohrleitung und Herstellungsverfahrendafür

    公开(公告)号：EP2682494A2

    公开(公告)日：2014-01-08

    申请号：EP13186005.8

    申请日：2005-06-29

    申请人： Nippon Steel & Sumitomo Metal Corporation

    发明人： Igarashi, Masaaki ,  Shimoda, Kazuhiro ,  Yamakawa, Tomio ,  Amaya, Hisashi

    IPC分类号： C22C38/00 ,  B21B19/04 ,  C21D8/10 ,  C22C19/05 ,  C22C38/58 ,  C22F1/10

    摘要： An Fe-Ni alloy pipe stock having a chemical composition comprising, by mass %, C ≤ 0.04%, Si ≤ 0.50%, Mn: 0.01 to 6.0%, P ≤ 0.03%, S ≤ 0.01%, Cr: 20 to 30%, Ni: 30 to 45%, Mo: 0 to 10%, W: 0 to 20%, with Mo(%) + 0.5W(%): more than 1.5% to not more than 10%, Cu: 0.01 to 1.5%, Al ≤ 0.01% and N: 0.0005 to 0.20%, and the balance substantially being Fe, with 1440 - 6000P - 100S - 2000C ≥ 1300, Ni + 10(Mo + 0.5W) + 100N ≤ 120, (Ni - 35) + 10(N - 0.1) - 2(Cr - 25) - 5(Mo + 0.5W - 3) + 8 ≥ 0, can be manufactured into a seamless pipe by use of a Mannesmann piercing and rolling mill because of its excellent inner surface properties. The resulting seamless pipe has excellent mechanical properties and moreover has excellent corrosion resistance in a sour gas environment, and thus, the Fe-Ni alloy pipe stock can be used as a pipe stock for oil country tubular goods and line pipes and further as a pipe stock for various structural members of nuclear power plants and chemical industrial plants.

    摘要翻译： 一种化学成分含量为C‰‰0.04％，Si‰0.50％，Mn：0.01〜6.0％，P‰0.03％，S‰‰0.01％的Fe-Ni合金管材， 20〜30％，Ni：30〜45％，Mo：0〜10％，W：0〜20％，Mo（％）+ 0.5W（％）：大于1.5％以上10％ ：0.01〜1.5％，Al‰0.01％，N：0.0005〜0.20％，余量基本为Fe，1440〜6000P-100S-2000C‰¥1300，Ni + 10（Mo + 0.5W）+ 100N‰ ¤120，（Ni-35）+ 10（N-0.1）-2（Cr-25）-5（Mo + 0.5W-3）+8‰¥0，可以通过使用Mannesmann 穿孔轧机由于其优异的内表面性能。 所得到的无缝管具有优异的机械性能，并且在酸性气体环境中具有优异的耐腐蚀性，因此，Fe-Ni合金管材可用作油料管状物料和管道管道的管材，还可用作管道 核电厂和化工厂各种结构成员的库存。

    IMAGING AGENTS
    20.
    发明公开
    IMAGING AGENTS 审中-公开
    造影剂

    公开(公告)号：EP2651454A1

    公开(公告)日：2013-10-23

    申请号：EP11808255.1

    申请日：2011-12-16

    申请人： Chroma Therapeutics Ltd.

    发明人： CHARLTON, Michael Hugh ,  MOFFAT, David Festus Charles ,  DAVIES, Steven John ,  DRUMMOND, Alan Hastings

    IPC分类号： A61K49/00 ,  C07D271/12 ,  C07F5/02

    CPC分类号： A61K49/0021 ,  C07D271/12 ,  C07F5/003 ,  C07F5/02 ,  G01N33/582

    摘要： An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hCE-1 relative to the intracellular enzymes hCE-2 or hCE-3.